Vimarsana
Biggest News Aggregation in the World

Severity Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Severity Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Severity Score Today - Breaking & Trending Today

Psychological Approaches Calm Functional Digestive Disorders - Vimarsana News

Psychological Approaches Calm Functional Digestive Disorders

Hypnosis, mindfulness meditation, and cognitive-behavioral therapy have shown particular benefits in irritable bowel syndrome.

Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles - Vimarsana News

Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles

In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.

Source: ajmc.com
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 ... - Vimarsana News

Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 ...

– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose –

Alumis Presents Positive Data from Phase 2 Clinical Trial - Vimarsana News

Alumis Presents Positive Data from Phase 2 Clinical Trial

Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024....

Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials - Vimarsana News

Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials

Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.

Source: ajmc.com